Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
33 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Cancer Therapeutics CRC Pty Ltd - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Cancer Therapeutics CRC Pty Ltd - Product Pipeline Review - 2014', provides an overview of the Cancer Therapeutics CRC Pty Ltd's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cancer Therapeutics CRC Pty Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cancer Therapeutics CRC Pty Ltd including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cancer Therapeutics CRC Pty Ltd's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cancer Therapeutics CRC Pty Ltd's pipeline products Reasons to buy - Evaluate Cancer Therapeutics CRC Pty Ltd's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cancer Therapeutics CRC Pty Ltd in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cancer Therapeutics CRC Pty Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cancer Therapeutics CRC Pty Ltd and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cancer Therapeutics CRC Pty Ltd - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Cancer Therapeutics CRC Pty Ltd and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Cancer Therapeutics CRC Pty Ltd Snapshot 5 Cancer Therapeutics CRC Pty Ltd Overview 5 Key Information 5 Key Facts 5 Cancer Therapeutics CRC Pty Ltd - Research and Development Overview 6 Key Therapeutic Areas 6 Cancer Therapeutics CRC Pty Ltd - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Cancer Therapeutics CRC Pty Ltd - Pipeline Products Glance 15 Cancer Therapeutics CRC Pty Ltd - Early Stage Pipeline Products 15 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Cancer Therapeutics CRC Pty Ltd - Drug Profiles 17 CTX-0294945 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Small Molecule Inhibiting Mitosis for Solid Tumors 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Small Molecule to Inhibit PRMT1 for Cancer 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Small Molecule to Inhibit USP7 for Cancer 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Small Molecules For Cancer 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Small Molecules to Inhibit FAK-FLT3-VEGFR3 for Oncology 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Small Molecules to Inhibit MELK for Cancer 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Small Molecules to Inhibit MOZ for Acute Myelocytic Leukemia 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 Small Molecules to Inhibit Ubiquitin E3 Ligase E6AP for Cancer 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Cancer Therapeutics CRC Pty Ltd - Pipeline Analysis 26 Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Target 26 Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Route of Administration 27 Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Molecule Type 28 Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Mechanism of Action 29 Cancer Therapeutics CRC Pty Ltd - Dormant Projects 30 Cancer Therapeutics CRC Pty Ltd - Locations And Subsidiaries 31 Head Office 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 33 Disclaimer 33
List of Tables Cancer Therapeutics CRC Pty Ltd, Key Information 5 Cancer Therapeutics CRC Pty Ltd, Key Facts 5 Cancer Therapeutics CRC Pty Ltd - Pipeline by Indication, 2014 8 Cancer Therapeutics CRC Pty Ltd - Pipeline by Stage of Development, 2014 9 Cancer Therapeutics CRC Pty Ltd - Monotherapy Products in Pipeline, 2014 10 Cancer Therapeutics CRC Pty Ltd - Partnered Products in Pipeline, 2014 11 Cancer Therapeutics CRC Pty Ltd - Partnered Products/ Combination Treatment Modalities, 2014 12 Cancer Therapeutics CRC Pty Ltd - Out-Licensed Products in Pipeline, 2014 13 Cancer Therapeutics CRC Pty Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 Cancer Therapeutics CRC Pty Ltd - Preclinical, 2014 15 Cancer Therapeutics CRC Pty Ltd - Discovery, 2014 16 Cancer Therapeutics CRC Pty Ltd - Pipeline by Target, 2014 26 Cancer Therapeutics CRC Pty Ltd - Pipeline by Route of Administration, 2014 27 Cancer Therapeutics CRC Pty Ltd - Pipeline by Molecule Type, 2014 28 Cancer Therapeutics CRC Pty Ltd - Pipeline Products by Mechanism of Action, 2014 29 Cancer Therapeutics CRC Pty Ltd - Dormant Developmental Projects,2014 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.